401 related articles for article (PubMed ID: 28680167)
21. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
Black HR
Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
[TBL] [Abstract][Full Text] [Related]
22. Novel RAAS agonists and antagonists: clinical applications and controversies.
Romero CA; Orias M; Weir MR
Nat Rev Endocrinol; 2015 Apr; 11(4):242-52. PubMed ID: 25666495
[TBL] [Abstract][Full Text] [Related]
23. Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review.
Li SM; He WB; Chen J; Cai QQ; Huang FF; Zhang K; Wang JF; Liu X; Huang H
Atherosclerosis; 2018 Feb; 269():35-41. PubMed ID: 29258005
[TBL] [Abstract][Full Text] [Related]
24. Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?
Mansur SJ; Hage FG; Oparil S
Curr Cardiol Rep; 2010 Nov; 12(6):450-63. PubMed ID: 20827517
[TBL] [Abstract][Full Text] [Related]
25. Should ACE inhibitors and ARBs be used in combination in children?
Stotter BR; Ferguson MA
Pediatr Nephrol; 2019 Sep; 34(9):1521-1532. PubMed ID: 30112656
[TBL] [Abstract][Full Text] [Related]
26. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
Brugts JJ; van Vark L; Akkerhuis M; Bertrand M; Fox K; Mourad JJ; Boersma E
Int J Cardiol; 2015 Feb; 181():425-9. PubMed ID: 25569271
[TBL] [Abstract][Full Text] [Related]
27. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
28. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
Abassi Z; Armaly Z; Nakhoul F; Hoffman A
Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
[TBL] [Abstract][Full Text] [Related]
29. Reducing cardiorenal risk through combination therapy with a direct renin inhibitor.
Rastogi A; Rashid M; Wright RF
J Clin Hypertens (Greenwich); 2011 Nov; 13(11):848-55. PubMed ID: 22051431
[TBL] [Abstract][Full Text] [Related]
30. ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects.
Silverstein RL; Fenves AZ; Ram CV
Postgrad Med; 2004 Aug; 116(2):31-8, 41. PubMed ID: 15323152
[TBL] [Abstract][Full Text] [Related]
31. The RAAS in the pathogenesis and treatment of diabetic nephropathy.
Ruggenenti P; Cravedi P; Remuzzi G
Nat Rev Nephrol; 2010 Jun; 6(6):319-30. PubMed ID: 20440277
[TBL] [Abstract][Full Text] [Related]
32. RAS inhibitors' dose-dependent efficacy: myth or reality?
Taddei S
Curr Med Res Opin; 2015; 31(7):1245-56. PubMed ID: 25985327
[TBL] [Abstract][Full Text] [Related]
33. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
34. Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: implications in heart failure management.
Beitelshees AL; Zineh I
Heart Fail Rev; 2010 May; 15(3):209-17. PubMed ID: 18351457
[TBL] [Abstract][Full Text] [Related]
35. Update on role of direct renin inhibitor in diabetic kidney disease.
Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V
Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
[TBL] [Abstract][Full Text] [Related]
36. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate.
Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
Diabetes Metab Syndr; 2012; 6(4):215-7. PubMed ID: 23199543
[TBL] [Abstract][Full Text] [Related]
37. Combined use of renin-angiotensin-aldosterone system-acting agents: a cross-sectional study.
Farcas A; Leucuta D; Bucsa C; Mogosan C; Dumitrascu D
Int J Clin Pharm; 2016 Dec; 38(6):1390-1397. PubMed ID: 27677980
[TBL] [Abstract][Full Text] [Related]
38. The renin-angiotensin-aldosterone system and heart failure.
Sayer G; Bhat G
Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
[TBL] [Abstract][Full Text] [Related]
39. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
Ferrari R; Boersma E
Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):705-17. PubMed ID: 23750680
[TBL] [Abstract][Full Text] [Related]
40. [The clinical usefulness of RAAS inhibitors in hypertensive patients].
Yamaguchi K; Sata M
Nihon Rinsho; 2012 Sep; 70(9):1571-6. PubMed ID: 23012805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
